NCT05978544尚未招募1 期
A Phase 1 Study to Evaluate the Safety, Tolerability and Preliminary Clinical Activity of Itolizumab in Subjects With Acute Respiratory Distress Syndrome Caused by Infectious Pneumonia
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 38
- 主要终点
- Incidence of Treatment Emergent Adverse Events
研究概览
简要总结
To evaluate the safety, tolerability, PK, PD, and clinical activity of Itolizumab in subjects with acute respiratory distress syndrome (ARDS) caused by Infectious Pneumonia.
详细描述
The study will enroll approximately 38 subjects in two parts:
Part 1 is an open label 3+3 single dose escalation phase. 9-24 patients with ARDS caused by infectious pneumonia across 3 dose cohorts.
Part 2 is a randomized phase and will enroll approximately 14 additional participants, randomized in a 1:1 ratio to one of the 2 doses based on efficacy data obtained from Part 1.
All participants in this study will receive Itolizumab intravenously for once, investigator discretion to continue with the same dose every 3 days up to 7 days.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female subject aged 18-75 years old (inclusive)
- •Clinical diagnosis with infectious pneumonia as determined by the investigator
- •Subject who havd received anti-infective treatment according to clinical practice.
- •Diagnosis with ARDS according to the following criteria: (i) Bilateral opacities-not fully explained by effusions, lobar/lung collapse, or nodules; (ii) respiratory failure not fully explained by cardiac failure or fluid overload; (iii) Oxygenation (PaO2/FiO2) ≤
- •ARDS diagnosed within 48 hours before administration, and fullfil the criteria of ARDS before administration
- •Fullfill at least 2 of the following 4 criteria: ① elevated hs-CRP (>6 ULN); ② elevated IL-6 (>3 ULN); ③ high serum ferritin (>500µg/L at any one time or more than 2-fold increase within 48 hours of onset); ④ high D-dimer (>3 ULN).
- •Negative result of serum HCG within 72 hours before enrollment for female with potential fertility
- •Participant or his/her legal representive (when the participant is not capable of giving consent) is able to understand and comply with the planned procedure as required by the protocol, and sign a written informed consent form (ICF)
排除标准
- •ARDS caused by non-infectious pneumonia (e.g., burns, drowning, poisoning, etc.)
- •Subject who has cardiogenic pulmonary edema, and it is the main cause of respiratory failure
- •Subject who is at high risk of death within 24 hours regardless of the treatment measures given as determined by the investigator
- •Subject who is receiving extracorporeal membrane pulmonary oxygenation (ECMO) therapy at the time of screening.
- •Subject who had received mechanical ventilation for more than 72 hours prior to administration.
- •Subject with active tumors (other than carcinoma in situ or basal cell carcinoma) that requiring treatment.
- •Any of the following chronic organ damage or immunosuppression:
- •Cardiac: cardiac arrest within 7 days prior to screening; New York Heart Association cardiac function class IV at screening;
- •Pulmonary: oxygen therapy or ventilator-dependent therapy for more than 1 month cumulatively within 6 months prior to screening; pulmonary embolism within 4 weeks prior to screening; pulmonary hypertension, end-stage lung disease, or interstitial lung disease requiring glucocorticoid therapy at screening;
- •Renal: serum creatinine > 1.5 ULN or creatinine clearance < 30 mL/min at screening (Cockcroft-Gault formula, see study protocol annex 5 for details) or on long-term dialysis treatment;
- •Liver: liver function classification of Child-Pugh grade C at screening;
- •Immunosuppression status: with lymphoma, leukemia or acquired immunodeficiency; having received antitumor chemotherapy in the last 3 months, or being treated with immunosuppression for organ transplantation or immune disorders; having had allogeneic bone marrow transplantation or allogeneic hematopoietic stem cell transplantation.
- •Subject who had vaccination within 28 days prior to administration, or plan to get the vaccine during the study period
- •Any of the following abnormalities at screening
- •Hepatitis B-related tests: ① positive for hepatitis B surface antigen (HBsAg); ② positive for hepatitis B core antibody (HBcAb); ③ positive for hepatitis B surface antibody (HBsAb) and no history of hepatitis B vaccination; ④ positive for hepatitis B e antigen or hepatitis B e antibody;
- •Positive hepatitis C virus antibody (HCV-Ab);
- •Positive acquired immunodeficiency syndrome antibody (HIV-Ab).
- •Subject who has a medical history of tuberculosis or those who deny a history of tuberculosis but has a positive gamma-interferon release test at screening.
- •Absolute lymphocyte count < 0.2×109/L at screening
- •Suspected allergic to the investigational drug or any of its excipients
- •Currently pregnant, breastfeeding,or planning to become pregnant or not using reliable method to avoid pregnancy during study and within 3 months after the last study treatment
- •Subject who had participated in other clinical studies (other than those not receiving interventions, such as observational study or questionnaires survey) within 3 months prior to screening, or who are participating in other experimental treatments.
- •As determined by the investigator, any medical, psychiatric, or other condition or circumstance that is likely to negatively affect the reliability of the study data.
研究组 & 干预措施
Itolizumab Dose Level 1
Experimental
Itolizumab of 50 mg administered by intravenous infusion for once, investigator discretion to continue with the same dose every 3 days up to 7 days.
干预措施: Itolizumab (Drug)
Itolizumab Dose Level 2
Experimental
Itolizumab of 100 mg administered by intravenous infusion for once, investigator discretion to continue with the same dose every 3 days up to 7 days.
干预措施: Itolizumab (Drug)
Itolizumab Dose Level 3
Experimental
Itolizumab of 150 mg administered by intravenous infusion for once, investigator discretion to continue with the same dose every 3 days up to 7 days.
干预措施: Itolizumab (Drug)
结局指标
主要结局
Incidence of Treatment Emergent Adverse Events
时间窗: Study Day 58
Number of subjects with treatment-related adverse events as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) V5.0
次要结局
- Maximum serum concentration of Itolizumab, Cmax(Study Day 30)
- Time to maximum serum concentration of Itolizumab, Tmax(Study Day 30)
- T cell subsets(Study Day 30)
- Minimum serum concentration of Itolizumab, Cmin(Study Day 30)
- Mechanical ventilation-free days(Study Day 30)
- Clinical status assessed using a 7-category ordinal scale(Study Day 30)
- Incidence of ADA(Study Day 30)
- Half life of Itolizumab, t1/2(Study Day 30)
- Inflammatory Markers,IL-6(Study Day 30)
- Inflammatory Markers, hs-CRP(Study Day 30)
- Inflammatory Markers,Serum ferritin(Study Day 30)
- Total Itolizumab exposure across time, AUC0-t(Study Day 30)
- Inflammatory Markers,TNF-α(Study Day 30)
- Mean change from baseline in SOFA score(Study Day 30)
- Oxygen therapy-free days(Study Day 30)
- Duration of ICU stay(Study Day 30)
- Mortality rate(Study Day 15, 30)
- Inflammatory Markers,D-dimer(Study Day 30)
- CD6 receptor expression levels(Study Day 30)
- The proportion of patients with stable or improved Lung Function(Study Day 30)
- Mean change from baseline in Murray Score(Study Day 30)
研究者
相似试验
尚未招募
1 期
Safety and Preliminary Clinical Activity of Itolizumab in DermatomyositisDermatomyositis, Adult TypeNCT05986162Biotech Pharmaceutical Co., Ltd.44
招募中
1 期
Safety and Clinical Activity of Itolizumab in aGVHDAcute Graft Versus Host DiseaseNCT05823675Biotech Pharmaceutical Co., Ltd.44
进行中（未招募）
1 期
Atezolizumab for Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisNCT05515627Cedars-Sinai Medical Center24
已完成
1 期
IBI322 Monotherapy or Combination Therapy in Subjects With Advanced Malignant Tumors.Advanced Solid TumorNCT04912466Innovent Biologics (Suzhou) Co. Ltd.61
已完成
2 期
Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic LeukemiaAcute Lymphocytic LeukemiaNCT01363297Pfizer72